Annual report pursuant to Section 13 and 15(d)

Collaborative Arrangements (Details)

v3.3.1.900
Collaborative Arrangements (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Aug. 31, 2015
Jul. 31, 2014
Feb. 29, 2012
Sep. 30, 2015
Dec. 31, 2014
Sep. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
GlaxoSmithKline (GSK) [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from license fees received       $ 6,000,000              
Revenue recognized           $ 6,500,000 $ 5,000,000        
Term of milestone agreement       3 years              
Eligible payment contingent upon completion of milestones and agreement       $ 7,500,000              
Minimum milestone receivable       5,750,000.00              
Maximum milestone receivable       $ 38,500,000.0              
License extension acceptance period       3 years              
Termination notice period       90 days              
License and service revenue           $ 2,000,000   $ 1,000,000      
Deferred Revenue $ 3,000,000           5,000,000   $ 3,000,000 $ 5,000,000  
Technology Transfer, Collaboration and License Agreement [Member] | Merck [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from license fees received     $ 5,000,000                
Revenue recognized   $ 5,000,000                  
Eligible payment contingent upon completion of milestones and agreement                 8,000,000    
Potential royalty revenue                 15,000,000    
License and service revenue                 1,000,000    
Deferred Revenue 4,000,000               4,000,000    
Upfront License fee, period for recognition     2 years                
One time contingent termination fee due from collaboration partner                 8,000,000    
Supply Agreement [Member] | Merck [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
License and service revenue                 1,900,000 2,000,000 $ 1,800,000
Deferred Revenue $ 1,000,000           $ 1,100,000   1,000,000 1,100,000  
Initial term of agreement (years)         5 years            
Additional Term of Agreement (years) 5 years                    
Arch [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Sales revenue, goods                 0 500,000 2,100,000
Merck [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Sales revenue, goods                 $ 1,600,000 $ 2,500,000 $ 1,000,000
Minimum | Merck [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
License extension acceptance period                 15 months    
Maximum | Merck [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
License extension acceptance period                 24 months